Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2022 Aug 19;17(8):e0271267. doi: 10.1371/journal.pone.0271267

Identified risk factors for dry eye syndrome: A systematic review and meta-analysis

Lijun Qian 1,2, Wei Wei 3,*
Editor: Michael Mimouni4
PMCID: PMC9390932  PMID: 35984830

Abstract

A meta-analytic approach was used to identify potential risk factors for dry eye syndrome. PubMed, Embase, and the Cochrane library were systematically searched for studies investigated the risk factors for dry eye syndrome from their inception until September 2021. The odds ratio (OR) with 95% confidence interval (CI) was calculated using the random-effects model. Forty-eight studies comprising 493,630 individuals were included. Older age (OR: 1.82; P<0.001), female sex (OR: 1.56; P<0.001), other race (OR: 1.27; P<0.001), visual display terminal use (OR: 1.32; P<0.001), cataract surgery (OR: 1.80; P<0.001), contact lens wear (OR: 1.74; P<0.001), pterygium (OR: 1.85; P = 0.014), glaucoma (OR: 1.77; P = 0.007), eye surgery (OR: 1.65; P<0.001), depression (OR: 1.83; P<0.001), post-traumatic stress disorder (OR: 1.65; P<0.001), sleep apnea (OR: 1.57; P = 0.003), asthma (OR: 1.43; P<0.001), allergy (OR: 1.38; P<0.001), hypertension (OR: 1.12; P = 0.004), diabetes mellitus (OR: 1.15; P = 0.019), cardiovascular disease (OR: 1.20; P<0.001), stroke (OR: 1.32; P<0.001), rosacea (OR: 1.99; P = 0.001), thyroid disease (OR: 1.60; P<0.001), gout (OR: 1.40; P<0.001), migraines (OR: 1.53; P<0.001), arthritis (OR: 1.76; P<0.001), osteoporosis (OR: 1.36; P = 0.030), tumor (OR: 1.46; P<0.001), eczema (OR: 1.30; P<0.001), and systemic disease (OR: 1.45; P = 0.007) were associated with an increased risk of dry eye syndrome. This study reported risk factors for dry eye syndrome, and identified patients at high risk for dry eye syndrome.

Introduction

Dry eye syndrome (DES) is defined as a multifactorial disease of the tears and ocular surface that could cause discomfort and visual disturbance, with potential damage to the ocular surface. These symptoms could affect quality of life and activities of daily living [1, 2]. The prevalence of DES is increasing and is seen in nearly one in five adults. Thus, this needs more attention from ophthalmologists [3, 4]. The role of the tear film has already been demonstrated. It has been shown to provide lubrication to the eyes, as well as nutrition and oxygen, and eliminate debris from the ocular surface [5]. Moreover, individuals with dry eyes also suffer from systemic diseases [4]. However, the prevalence of dry eyes is often underestimated because of varying presentation and symptoms [6]. Studies have demonstrated that age and sex are significantly associated with increased risk of DES; however, the pathogenesis of DES is not fully understood [7, 8].

Several studies have already identified risk factors for DES. Major risk factors include older age, female sex, having undergone postmenopausal estrogen therapy or ocular surface surgery, and using antihistamine medications [9]. Moreover, the occupational risk factor of visual display terminal (VDT) use was related to the progression of DES, which could be explained by a decreased blink rate and increased proportion of incomplete blinks that could be caused by the increased exposure of the ocular surface to the environment. Outdoor environments, sunlight, and air pollution in tropical countries are also associated with an elevated risk of DES [10, 11]. Furthermore, other risk factors for DES include vitamin D deficiency and diabetes mellitus (DM) [12, 13]. However, whether the comorbidities of individuals could affect the risk of DES remained controversial. We, therefore, performed a systematic review and meta-analysis to independently identify risk factors for DES.

Methods

Data sources, search strategy, and selection criteria

The current study was performed and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement [14]. Studies reporting the risk factors of DES were eligible in our study, and publication language was restricted to English. PubMed, Embase, and the Cochrane library were systematically searched for eligible studies from their inception until September 2021, and using the following text word or Medical Subject Heading terms: "dry eye syndrome", "dry eye disease", "Keratoconjunctivitis Sicca", "Xerophthalmia", and "Risk Factors". The details of search strategy in PubMed are listed in S1 File. The reference lists of relevant original and review articles were manually screened to identify further eligible studies.

Two reviewers (QL and WW) independently performed study assessment following a standardized approach. Any disagreement between reviewers was settled by discussion until a consensus was reached. A study was included if the following criteria were met: (1) it was a cross-sectional, retrospective, or prospective observational study; (2) risk factors were reported for ≥ 3 studies [15] and included such factors as age, sex, race, residence, education level, obesity, dyslipidemia, alcohol, smoking, VDT use, cataract surgery, contact lens wear, pterygium, glaucoma, age-related maculopathy, eye surgery, depression, post-traumatic stress disorder (PTSD), sleep apnea, asthma, allergy, hypertension, DM, cardiovascular disease (CVD), stroke, rosacea, thyroid disease, chronic obstructive pulmonary disease (COPD), gout, migraines, arthritis, osteoporosis, tumor, meibomian gland dysfunction (MGD), eczema, and systemic disease; and (3) it reported effect estimates (relative risk [RR], hazard ratio [HR], or odds ratio [OR]) and 95% confidence interval (CI) for risk factors of DES. Interventional study, animal study, review, and letter to editor was excluded.

Data collection and quality assessment

Two reviewers (QL and WW) independently abstracted the following items, including study group or first author’s name, publication year, country, study design, sample size, age, % of males, population status, % of DES cases, definition of DES, risk factors, adjusted factors, and reported effect estimates. The effect estimate with maximal adjustment for potential confounders was selected if a study reported several multivariable-adjusted effect estimates. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), which has already been validated for assessing the quality of observational studies in meta-analysis [16]. A total of 8 items in 3 subscales were included in NOS. The star system in each study ranged from 0–9. Inconsistent results for the data abstracted and quality assessment between the two reviewers were settled following mutually discussion referred to the original article.

Statistical analysis

Identified risk factors for DES were analyzed based on the OR, RR, or HR, with its 95% CI, in individual studies. Then the pooled ORs with 95%CI were calculated using the random-effects model [17, 18]. I2 and Q statistic were applied to assess heterogeneity across included studies. Significant heterogeneity was defined as I2> 50.0% or P < 0.10 [19, 20]. Sensitivity analysis was performed for factors reported in ≥ 4 studies to assess the robustness of pooled conclusion through sequentially removing individual studies [21]. Subgroup analyses were performed for factors reported in ≥ 4 studies on the basis of the country. The difference between subgroups was assessed using the interaction P test [22]. Visual inspections of funnel plots for factors reported in ≥ 4 studies were performed to qualitatively assess publication bias. The Egger or Begg tests were used to quantitatively assess publication bias [23, 24]. The P-value for all pooled results was 2-sided, and the inspection level was 0.05. All of the statistical analysis in our study was performed using software STATA (version 12.0; Stata Corporation, College Station, TX, USA).

Results

Literature search

A total of 1,672 studies were identified from initial electronic searches. Details of the study selection process are presented in Fig 1. Of these, 912 articles were removed because they were duplicates. A further 671 articles were excluded owing to irrelevant titles or abstracts. The remaining 89 studies were retrieved for full-text evaluations, with 41 studies removed because of: affiliate study (n = 23), evaluated factors < 3 studies (n = 12), and review-type articles (n = 6). A manual search of the reference lists of relevant articles did not yield any additional studies. Finally, 48 studies were selected for the final meta-analysis [25–71]. Characteristics of the included studies and involved individuals are summarized in Table 1.

Fig 1. Details of the literature search and study selection processes.

Fig 1

Open in a new tab

Table 1. The baseline characteristics of included studies.

Study Country Study design Sample size Age (years) Male (%) Population DES (%) Definition of DES Reported factors Adjusted factors
BDES 2000 [25] USA C 3,722 65.0 43.0 PB 14.4 Questionnaire DM, arthritis, TD, osteoporosis, gout, ES, CLW, alcohol, smoking Age and sex
Lee 2002 [26] Indonesia C 1,058 37.0 47.7 PB 27.5 Questionnaire Sex, smoking, pterygium Sex, age, occupation, smoking, and pterygium
BMES 2003 [27] Australia C 1,174 60.8 44.2 PB 57.5 Questionnaire Arthritis, asthma, DM, gout, smoking, alcohol Age and sex
Sahai 2005 [28] India C 500 > 20.0 55.2 HB 18.4 Questionnaire Smoking Age and sex
Nichols 2006 [29] USA C 360 31.1 32.0 HB 55.3 Questionnaire Sex Nominal water content, PLTF
Uchino 2008 [30] Japan C 3,549 22.0–60.0 74.4 PB 10.1 Questionnaire Age, sex, VDT, systemic disease, smoking, contact lens Age, gender, VDT use, systemic disease systemic medication, smoking, contact lens use
Lu 2008 [31] China C 1,840 56.3 56.0 PB 52.4 TFBT, ST, FSS Age, education level, smoking alcohol Crude
PHS 2009 [32] USA C 25,444 64.4 100.0 PB 23.0 Questionnaire Age, race, hypertension, tumor, DM Crude
TSES 2009 [33] Spain C 654 63.6 37.2 PB 11.0 Questionnaire Sex, VDT use, CLW, rosacea, allergy, DM, hypertension, COPD, education level, alcohol, smoking Age and sex
BES 2009 [34] China C 1,957 56.5 43.1 PB 21.0 Questionnaire Sex, residence, glaucoma, MD, DM, hypertension, smoking, alcohol Age, sex, region, undercorrection of refractive error, and nuclear cataract
THES 2010 [35] China C 1,816 54.9 53.9 PB 50.1 TBUT, ST, FSS Pterygium, age, sex, education level, smoking, alcohol Crude
Kim 2011 [36] Korea C 650 71.9 48.3 PB 30.5 Questionnaire Sex, residence, depression, MGD Crude
Koumi Study 2011 [37] Japan C 2,791 > 40.0 43.7 PB 16.5 Questionnaire Age, smoking, alcohol, BMI, education level, VDT use, CLW, stroke, CVD, hypertension, DM Age, smoking, alcohol, BMI, education level, VDT use, CLW, stroke, CVD, hypertension, DM
USVAP 2011 [38] USA R 16,862 NA NA PB 12.2 ICD9 code Sex, race, DM, hypertension, dyslipidemia, CVD, stroke, PTSD, depression, alcohol, arthritis, gout, TD, tumor, sleep apnea, rosacea, glaucoma Age and sex
Zhang 2012 [39] China C 1,885 < 18.0 50.8 PB 23.7 Questionnaire CLW, sleep apnea CLW, sleep apnea, myopia, inadequate refractive correction, topical ophthalmic medication
TNHRI 2012 [40] China R 48,028 52.4 26.6 PB 25.0 ICD9 code Hypertension,CVD, dyslipidemia, stroke, migraines, arthritis, COPD, asthma, DM, TD, depression, and tumor Age, sex, region, and incomes
TOS 2013 [41] Japan C 561 43.3 66.7 PB 11.6 Questionnaire Sex, age, smoking, VDT use, CLW, systemic disease, hypertension Sex, age, smoking, VDT use, CLW, systemic disease, hypertension
TwinUK 2014 [42] UK C 3,824 57.1 0.0 PB 9.6 Questionnaire CLW, CS, glaucoma, MD, osteoporosis, asthma, allergy, TD, arthritis, dyslipidemia, hypertension, DM, cancer, stroke, migraine, depression Age
KNHNES 2014 [43] Korea C 11,666 49.9 42.8 PB 8.0 Questionnaire Age, sex, education level, residence, hypertension, obesity, dyslipidemia, arthritis, TD, smoking, alcohol, sleep apnea, ES Age, sex, education level, residence, hypertension, obesity, dyslipidemia, arthritis, TD, smoking, alcohol, sleep apnea, ES
Moon 2014 [44] Korea C 288 10.9 49.3 PB 9.7 Questionnaire VDT use Age, and sex
BDOS 2014 [45] USA C 3,275 49.0 45.4 PB 14.5 Questionnaire Age, sex, CLW, arthritis, allergies, TD, migraine Age, and sex
TNHI 2015 [46] China R 10,325 61.9 36.7 PB 20.0 ICD9 code DM, hypertension, dyslipidemia, CVD DM, hypertension, dyslipidemia, CVD
Yang 2015 [47] China R 1,908 56.2 41.4 HB 41.4 TFBT, ST, and FSS DM, arthritis, tumor, acne rosacea, PTSD, VDT use DM, arthritis, tumor, acne rosacea, PTSD, VDT use
Tan 2015 [48] Singapore C 1,004 38.2 44.1 PB 12.3 Questionnaire Sex, age, CLW, alcohol Crude
Shah 2015 [49] India C 400 58.6 48.0 HB 54.3 TBUT DM, ES, MGD Occupation, indoor table work, DM previous ocular surgery, MGD
Olaniyan 2016 [50] Nigeria C 363 59.1 48.2 PB 32.5 Questionnaire Age, ES Age, work place, medication use, ocular surgery, postmenopausal state
Alshamrani 2017 [51] Saudi Arabia C 1,858 39.3 48.0 PB 32.1 Questionnaire Sex, age, residence, smoking, CLW, DM, hypertension, asthma, CVD, TD, arthritis, gout, osteoporosis Sex, age, residence, work status, smoking, currently wearing, and history of trachoma
NHWS 2017 [52] USA C 73,211 > 18.0 48.4 PB 6.9 Questionnaire Age, sex, race, education level Age and sex
SMES 2017 [53] Singapore P 1,682 56.9 44.6 PB 5.1 Questionnaire DM, hypertension, smoking, CLW, stroke, CVD, TD, glaucoma, MGD, pterygium Sex, age, income, smoking, CLW, cataract surgery, thyroid disease
Gong 2017 [54] China C 1,015 54.6 29.7 PB 27.8 Questionnaire VDT use, DM, hypertension, arthritis, smoking, alcohol Sex, age, VDT use, DM, hypertension, arthritis, dry mouth, smoking, alcohol, and spicy diets
Asiedu 2017 [54] Ghana C 650 22.0 66.6 PB 44.3 Questionnaire Age, sex, allergies, alcohol, VDT use Age, sex, allergies, alcohol, VDT use
Graue-Hernandez 2018 [55] Mexico C 1,508 64.7 40.3 PB 41.1 Questionnaire Sex, smoking, DM, alcohol, hypertension Sex, smoking, DM, alcohol, hypertension
SES 2018 [56] Spain C 264 56.8 32.7 PB 25.4 TBUT, ST, FSS Sex, education level, VDT use, alcohol, smoking, hypertension, DM, COPD, CVD, TD, rosacea Age
Iglesias 2018 [57] USA R 86 71.0 95.0 HB 32.1 Questionnaire Race, DM, depression, PTSD, sleep apnea, glaucoma Crude
TMS 2018 [58] France C 1,045 82.2 71.8 PB 34.4 Questionnaire Obesity, smoking, alcohol, education level, hypertension, DM, depression, CS, MD, glaucoma Age, and sex
Shehadeh-Mashor 2019 [59] Israel R 25,317 27.0 55.0 PB 6.0 TBUT, and ST Sex, CLW Age and sex
Zhang 2019 [60] China C 31,124 NA 49.1 HB 57.6 ST, and FSS Sex, age, DM, arthritis, TD, ES Sex, age, refractive surgery
Yasir 2019 [61] Saudi Arabia C 890 > 40.0 55.5 PB 35.9 Questionnaire Glaucoma, DM, and hypertension Crude
HTS 2019 [62] Japan C 356 55.5 37.4 PB 33.4 Questionnaire Sex, smoking, CLW, hypertension Sex, eye makeup use, smoking CLW, hypertension, sleeping pills
Hyon 2019 [63] Korea C 232 > 20.0 15.1 PB 42.7 Questionnaire Sex, VDT use Sex, and VDT use
Ben-Eli 2019 [64] Israel R 331 53.6 24.8 HB 36.3 Clinician-diagnosed Smoking, alcohol Ethnicity, smoking, alcohol, hospitalization for infection
Yu 2019 [65] China C 23,922 NA 48.8 HB 61.6 TBUT, and FSS Sex, age, ES, arthritis, TD Humidity, air pressure, and air temperature
Rossi 2019 [66] Italy C 194 41.8 34.5 HB 16.5 TBUT, and FSS Sex, VDT use Age, sex, VDT use, visual acuity, and presbyopia
Wang 2020 [67] New Zealand C 372 39.0 40.3 PB 29.0 Clinician-diagnosed Sex, CLW, anxiety, asthma, DM, depression, dyslipidemia, hypertension, cancer, migraine, TD, CS, ES Age, CLW, ethnicity, migraine, menopause, systemic disease, thyroid disease, antidepressant medication, and oral contraceptive therapy
Shanti 2020 [68] Palestine C 769 43.6 47.3 PB 64.0 TBUT, ST, FSS Sex, VDT use, smoking, DM, hypertension Age, sex, VDT use, smoking, systemic disease
JPHC 2020 [69] Japan P 102,582 58.3 46.2 PB 24.6 Questionnaire VDT use Age, smoking, education status, income, and public health area
Alkabbani 2021 [70] United Arab Emirates C 452 > 17.0 36.3 PB 62.6 Questionnaire Age, sex, CLW, ES, VDT use, smoking Age, sex, CLW, ES, VDT use, smoking
LCS 2021 [71] Netherlands C 79,866 50.4 40.8 PB 9.1 Questionnaire Sex, CLW, MD, glaucoma, ES, CS, arthritis, gout, CVD, stroke, migraine, depression, PTSD, COPD, asthma, sleep apnea, rosacea, allergy, DM, osteoporosis, TD, anemia Age, and sex
Open in a new tab

*BMI: body mass index; C: cross-sectional; CLW: contact lens wear; COPD: chronic obstructive pulmonary disease; CS: cataract surgery; CVD: cardiovascular disease; DM: diabetes mellitus; ES: eye surgery; FSS: fluorescein staining score; HB: hospital-based; MD: macular degeneration; MDG: meibomian gland dysfunction; MI: myocardial infarction; NA: not available; P: prospective; PB: population-based; PLTF: prelens tear film; PTSD: post-traumatic stress disorder; R: retrospective; ST: Schirmer test; TBUT: tear film break-up time; TD: thyroid disease; TFBT: tear film breakup time; VDT: visual display terminal

Study characteristics

Of 48 included studies, 39 studies were designed as cross-sectional, 7 studies were designed as retrospective, and 2 studies designed as prospective. A total of 493,630 individuals were included, and the sample size ranged from 86 to 102,582. The mean age of included individuals ranged from 10.9 to 82.2. Twenty-nine studies were performed in Eastern countries, with the remaining 19 studies conducted in Western countries. Thirty-nine studies were population based. The remaining 9 studies were hospital based. The DES definition based on questionnaire were reported in 33 studies, 10 studies used TBUT, ST, or FSS defined DES, 3 studies applied ICD9 code and the remaining 2 studies used clinician-diagnosed defined DES. Study quality was assessed using the NOS; 11 studies had 8 stars, 18 had 7 stars, and the remaining 19 had 6 stars (S1 Table). The quality of included studies mainly affect by the representativeness of the exposed cohort, and comparability on the basis of the design or analysis.

Meta-analysis

Demographic factors

The number of studies that reported on the association of age, sex, and race as risk factors for DES was 15, 29, and 5, respectively (Fig 2 and S2 File). We noted that older adults (OR: 1.82; 95%CI: 1.47–2.26; P<0.001), females (OR: 1.56; 95%CI: 1.36–1.78; P<0.001), and those of other race (OR: 1.27; 95%CI: 1.11–1.44; P<0.001) had an increased risk of DES. There was significant heterogeneity for age (I2 = 96.0%; P<0.001), sex (I2 = 95.0%; P<0.001), and race (I2 = 52.1%; P = 0.080). Sensitivity analysis indicated these pooled conclusions were robust and not altered by sequentially excluding individual studies (S3 File). The results of subgroup analyses were consistent with overall analysis when stratified according to the region (Table 2). There were no significant publication biases for age (P-value for Egger: 0.175; P-value for Begg: 1.000), sex (P-value for Egger: 0.417; P-value for Begg: 0.253), and race (P-value for Egger: 0.174; P-value for Begg: 0.806) regarding risk for DES (S4 File).

Fig 2. Summary results of risk factors for dry eye syndrome.

Fig 2

Open in a new tab
Table 2. Subgroup analyses according to region.
Factors Subgroup OR and 95%CI P value I2 (%) P heterogeneity P value between subgroups
Age (elderly versus younger) Eastern countries 1.78 (1.46–2.19) < 0.001 89.4 < 0.001 < 0.001
Western countries 2.04 (1.05–3.97) 0.036 98.7 < 0.001
Sex (female versus male) Eastern countries 1.53 (1.36–1.72) < 0.001 84.0 < 0.001 < 0.001
Western countries 1.52 (1.20–1.92) < 0.001 95.8 < 0.001
Race (other versus white) Eastern countries - - - - -
Western countries 1.27 (1.11–1.44) < 0.001 52.1 0.080
Residence (urban versus rural) Eastern countries 1.41 (0.96–2.08) 0.078 87.8 < 0.001 -
Western countries - - - -
Education level (high versus low) Eastern countries 1.28 (1.01–1.63) 0.041 60.2 0.057 0.007
Western countries 0.86 (0.56–1.33) 0.505 80.7 0.001
Obesity Eastern countries 1.02 (0.83–1.25) 0.866 2.1 0.360 0.685
Western countries 1.11 (0.77–1.60) 0.576 - -
Dyslipidemia Eastern countries 1.35 (1.01–1.80) 0.046 94.7 < 0.001 < 0.001
Western countries 1.05 (0.82–1.35) 0.676 77.2 0.004
Alcohol Eastern countries 1.04 (0.90–1.20) 0.589 0.0 0.429 0.177
Western countries 0.92 (0.64–1.32) 0.641 76.1 <0.001
Smoking Eastern countries 0.96 (0.81–1.15) 0.668 65.2 < 0.001 0.046
Western countries 1.09 (0.82–1.45) 0.554 60.0 0.020
VDT use Eastern countries 1.33 (1.17–1.53) < 0.001 85.5 < 0.001 0.436
Western countries 1.33 (1.06–1.68) 0.015 0.0 0.457
Cataract surgery Eastern countries 2.16 (1.62–2.89) < 0.001 0.0 0.792 0.561
Western countries 1.69 (1.28–2.21) < 0.001 76.0 0.002
Contact lens wear Eastern countries 2.01 (1.48–2.71) <0.001 72.8 <0.001 0.003
Western countries 1.41 (0.93–2.14) 0.105 97.1 <0.001
Pterygium Eastern countries 1.85 (1.13–3.01) 0.014 89.0 < 0.001 -
Western countries - - - -
Glaucoma Eastern countries 2.15 (1.29–3.58) 0.003 26.1 0.255 0.516
Western countries 1.57 (0.92–2.68) 0.098 96.5 < 0.001
Age-related maculopathy Eastern countries 0.31 (0.07–1.35) 0.118 - - 0.007
Western countries 1.91 (1.21–3.01) 0.005 62.9 0.067
Eye surgery Eastern countries 1.62 (1.23–2.14) 0.001 93.6 <0.001 <0.001
Western countries 1.82 (1.39–2.37) < 0.001 32.1 0.229
Depression Eastern countries 2.12 (1.95–2.32) < 0.001 0.0 0.876 < 0.001
Western countries 1.66 (1.43–1.93) < 0.001 67.0 0.010
PTSD Eastern countries 1.45 (1.04–2.01) 0.027 - - 0.121
Western countries 1.71 (1.19–2.46) 0.004 53.0 0.119
Sleep apnea Eastern countries 1.22 (1.11–1.35) < 0.001 4.5 0.370 < 0.001
Western countries 2.17 (1.95–2.41) < 0.001 0.0 0.749
Asthma Eastern countries 1.19 (0.98–1.45) 0.076 29.0 0.235 < 0.001
Western countries 1.62 (1.49–1.77) < 0.001 0.0 0.869
Allergy Eastern countries - - - - -
Western countries 1.38 (1.32–1.45) < 0.001 0.0 0.418
Hypertension Eastern countries 1.06 (0.95–1.17) 0.306 63.7 0.001 0.005
Western countries 1.27 (1.14–1.41) < 0.001 24.8 0.231
DM Eastern countries 1.20 (1.06–1.37) 0.005 79.0 < 0.001 < 0.001
Western countries 1.08 (0.87–1.34) 0.460 88.5 < 0.001
CVD Eastern countries 1.26 (1.15–1.39) < 0.001 0.0 0.753 0.084
Western countries 1.15 (1.00–1.32) 0.049 18.5 0.293
Stroke Eastern countries 1.31 (1.22–1.41) < 0.001 0.0 0.978 0.667
Western countries 1.35 (1.20–1.51) < 0.001 0.0 0.589
Rosacea Eastern countries 3.75 (1.97–7.12) < 0.001 - - 0.032
Western countries 1.74 (1.20–2.52) 0.004 53.1 0.094
Thyroid disease Eastern countries 1.57 (1.29–1.91) < 0.001 86.0 <0.001 0.752
Western countries 1.64 (1.45–1.84) < 0.001 26.9 0.223
COPD Eastern countries 1.06 (0.84–1.34) 0.625 - - 0.006
Western countries 1.37 (1.00–1.89) 0.051 23.2 0.272
Gout Eastern countries 1.56 (0.70–3.49) 0.275 83.3 0.014 0.175
Western countries 1.34 (1.17–1.53) < 0.001 0.0 0.860
Migraines Eastern countries 1.76 (1.57–1.98) < 0.001 - - < 0.001
Western countries 1.41 (1.19–1.68) < 0.001 54.2 0.088
Arthritis Eastern countries 1.74 (1.31–2.29) < 0.001 95.6 < 0.001 0.776
Western countries 1.80 (1.57–2.07) < 0.001 74.7 0.001
Osteoporosis Eastern countries 0.81 (0.51–1.29) 0.377 - - 0.004
Western countries 1.53 (1.21–1.93) < 0.001 75.8 0.016
Tumor Eastern countries 2.27 (0.83–6.22) 0.111 94.7 < 0.001 0.339
Western countries 1.33 (1.17–1.50) <0.001 39.5 0.175
Open in a new tab

The number of studies reporting an association of residence, education level, obesity, and dyslipidemia regarding the risk of DES were 4, 8, 4, and 7, respectively (Fig 2 and S2 File). We noted that residence (urban versus rural) (OR: 1.41; 95%CI: 0.96–2.08; P = 0.078), education level (high versus low) (OR: 1.09; 95%CI: 0.88–1.34; P = 0.443), obesity (OR: 1.04; 95%CI: 0.87–1.24; P = 0.671), and dyslipidemia (OR: 1.18; 95%CI: 0.97–1.45; P = 0.104) were not associated with increased risk for DES. There was significant heterogeneity for residence (I2 = 87.8%; P<0.001), education level (I2 = 76.9%; P<0.001), and dyslipidemia (I2 = 92.9%; P<0.001), while there was no evidence of heterogeneity for obesity (I2 = 0.0%; P = 0.530). Sensitivity analyses indicated that residence, education level, and dyslipidemia might be associated with an elevated risk of DES, while the association between obesity and DES persisted (S3 File). Subgroup analyses demonstrated that education level and dyslipidemia were associated with an increased risk of DES when pooling studies conducted in Eastern countries (Table 2). No significant publication bias for residence (P-value for Egger: 0.875; P-value for Begg: 0.734), education level (P-value for Egger: 0.985; P-value for Begg: 0.902), and obesity (P-value for Egger: 0.638; P-value for Begg: 0.308) with the risk of DES was noted, whereas potential significant publication bias for dyslipidemia (P-value for Egger: 0.037; P-value for Begg: 1.000) with the risk of DES was seen (S4 File).

The number of studies reporting an association of alcohol, smoking, and VDT use with the risk of DES was 15, 22, and 14, respectively (Fig 2 and S2 File). We noted that alcohol intake (OR: 0.98; 95%CI: 0.81–1.18; P = 0.808) and current smoking (OR: 1.00; 95%CI: 0.86–1.16; P = 0.986) were not associated with risk for DES, while VDT use was associated with an increased risk of DES (OR: 1.32; 95%CI: 1.17–1.49; P<0.001). There was significant heterogeneity for alcohol (I2 = 62.2%; P = 0.001), smoking (I2 = 64.6%; P<0.001), and VDT use (I2 = 80.1%; P<0.001). Sensitivity analysis indicated that alcohol intake might play an important role in the risk of DES, while the pooled results for the associations of smoking and VDT use with the risk of DES were robust (S3 File). The results of subgroup analyses were consistent with the overall analysis (Table 2). No significant publication bias for smoking (P-value for Egger: 0.569; P-value for Begg: 0.822) and VDT use (P-value for Egger: 0.370; P value for Begg: 0.827) with the risk of DES was found, whereas potential significant publication bias for alcohol (P-value for Egger: 0.032; P-value for Begg: 0.921) with the risk of DES was noted (S4 File).

Clinical characteristics

The number of studies that reported on the association of cataract surgery, contact lens wear, pterygium, glaucoma, age-related maculopathy, and eye surgery with the risk of DES were 7, 17, 4, 9, 3, and 8, respectively (Fig 2 and S2 File). We noted that cataract surgery (OR: 1.80; 95%CI: 1.46–2.21; P<0.001), contact lens wear (OR: 1.74; 95%CI: 1.34–2.25; P<0.001), pterygium (OR: 1.85; 95%CI: 1.13–3.01; P = 0.014), glaucoma (OR: 1.77; 95%CI: 1.17–2.69; P = 0.007), and eye surgery (OR: 1.65; 95%CI: 1.31–2.07; P<0.001) were associated with an increased risk of DES, while age-related maculopathy was not associated with risk of DES (OR: 1.46; 95%CI: 0.79–2.70; P = 0.231). Significant heterogeneity was noted for cataract surgery (I2 = 64.8%; P<0.001), contact lens wear (I2 = 93.5%; P<0.001), pterygium (I2 = 89.0%; P<0.001), glaucoma (I2 = 93.4%; P<0.001), age-related maculopathy (I2 = 76.5%; P = 0.005), and eye surgery (I2 = 94.0%; P<0.001) with the risk of DES. Sensitivity analyses indicated that the pooled results for the association of cataract surgery, contact lens wear, pterygium, glaucoma, and eye surgery with the risk of DES persisted, whereas age-related maculopathy might be associated with the risk of DES (S3 File). Although most results in the subgroup analyses were consistent with the overall analysis, we noted that contact lens wear and glaucoma were not associated with the risk of DES when pooling studies performed in Western countries. Moreover, age-related maculopathy was associated with an increased risk of DES when pooling studies conducted in Western countries (Table 2). There was no significant publication bias for the association of cataract surgery (P-value for Egger: 0.194; P-value for Begg: 0.548), contact lens wear (P-value for Egger: 0.791; P-value for Begg: 0.387), pterygium (P-value for Egger: 0.681; P-value for Begg: 0.734), glaucoma (P-value for Egger: 0.950; P-value for Begg: 0.917), and eye surgery (P-value for Egger: 0.760; P-value for Begg: 0.266) with the risk of DES, while potential significant publication bias was noted for age-related maculopathy (P-value for Egger: 0.017; P-value for Begg: 0.308) with the risk of DES (S4 File).

Comorbidities

The number of studies that reported on the association of depression, PTSD, sleep apnea, asthma, and allergy with the risk of DES were 9, 4, 7, 6, and 6, respectively (Fig 2 and S2 File). We noted that depression (OR: 1.83; 95%CI: 1.57–2.12; P<0.001), PTSD (OR: 1.65; 95%CI: 1.26–2.15; P<0.001), sleep apnea (OR: 1.57; 95%CI: 1.16–2.11; P = 0.003), asthma (OR: 1.43; 95%CI: 1.20–1.71; P<0.001), and allergy (OR: 1.38; 95%CI: 1.32–1.45; P<0.001) were associated with an increased risk of DES. There was significant heterogeneity for depression (I2 = 80.7%; P<0.001), PTSD (I2 = 55.0%; P = 0.083), sleep apnea (I2 = 91.5%; P<0.001), and asthma (I2 = 76.5%; P = 0.001), while no evidence of heterogeneity for allergy was observed (I2 = 0.0%; P = 0.418). Sensitivity analyses indicated that pooled conclusions for the association of depression, PTSD, sleep apnea, asthma, and allergy with the risk of DES were stable after sequentially removing individual studies (S3 File). The results of subgroup analyses were consistent with overall analysis, except that asthma was not associated with the risk of DES if pooled studies were performed in Eastern countries (Table 2). No significant publication bias for the role of depression (P-value for Egger: 0.679; P-value for Begg: 0.348), PTSD (P-value for Egger: 0.415; P-value for Begg: 0.734), sleep apnea (P-value for Egger: 0.959; P-value for Begg: 0.764), asthma (P-value for Egger: 0.949; P-value for Begg: 1.000), and allergy (P-value for Egger: 0.189; P-value for Begg: 0.707) with DES were observed (S4 File).

The number of studies reporting on the association of hypertension, DM, CVD, stroke, rosacea, thyroid disease, and COPD with the risk of DES were 21, 24, 8, 7, 5, 14, and 4, respectively (Fig 2 and S2 File). We noted that hypertension (OR: 1.12; 95%CI: 1.04–1.22; P = 0.004), DM (OR: 1.15; 95%CI: 1.02–1.29; P = 0.019), CVD (OR: 1.20; 95%CI: 1.12–1.29; P<0.001), stroke (OR: 1.32; 95%CI: 1.24–1.40; P<0.001), rosacea (OR: 1.99; 95%CI: 1.34–2.95; P = 0.001), and thyroid disease (OR: 1.60; 95%CI: 1.42–1.80; P<0.001) were associated with an increased risk of DES, while COPD was not associated with risk of DES (OR: 1.22; 95%CI: 10.90–1.66; P = 0.202). There was significant heterogeneity for hypertension (I2 = 60.2%; P<0.001), DM (I2 = 86.7%; P<0.001), rosacea (I2 = 63.6%; P = 0.027), thyroid disease (I2 = 74.6%; P<0.001), and COPD (I2 = 70.6%; P = 0.017), while no significant heterogeneity was observed for CVD (I2 = 4.8%; P = 0.393) and stroke (I2 = 0.0%; P = 0.964). The pooled conclusions for the association of hypertension, CVD, stroke, rosacea, and thyroid disease with the risk of DES were stable, while the conclusions for DM and COPD with DES were variable (S3 File). Although the results of subgroup analyses were consistent with the overall analysis in most subsets, we noted that hypertension was not related to DES if pooling in Eastern country studies, while DM was not associated with the risk of DES if pooled studies were performed in Western countries (Table 2). There was no significant publication bias for hypertension (P-value for Egger: 0.331; P-value for Begg: 0.928), DM (P-value for Egger: 0.765; P-value for Begg: 0.862), CVD (P-value for Egger: 0.357; P-value for Begg: 0.711), stroke (P-value for Egger: 0.485; P-value for Begg: 0.368), rosacea (P-value for Egger: 0.759; P-value for Begg: 0.806), thyroid disease (P-value for Egger: 0.996; P-value for Begg: 0.228), and COPD (P-value for Egger: 0.267; P-value for Begg: 1.000) (S4 File).

The number of studies reporting on the association of gout, migraines, arthritis, osteoporosis, tumor, MGD, eczema, and systemic disease with the risk of DES was 6, 5, 13, 4, 6, 3, 3, and 3, respectively (Fig 2 and S2 File). We noted that gout (OR: 1.40; 95%CI: 1.17–1.68; P<0.001), migraines (OR: 1.53; 95%CI: 1.25–1.89; P<0.001), arthritis (OR: 1.76; 95%CI: 1.51–2.05; P<0.001), osteoporosis (OR: 1.36; 95%CI: 1.03–1.80; P = 0.030), tumor (OR: 1.46; 95%CI: 1.23–1.76; P<0.001), eczema (OR: 1.30; 95%CI: 1.22–1.38; P<0.001), and systemic disease (OR: 1.45; 95%CI: 1.11–1.91; P = 0.007) were associated with an increased risk of DES, while MGD was not associated with risk of DES (OR: 2.47; 95%CI: 0.79–7.70; P = 0.119). There was significant heterogeneity for migraines (I2 = 86.4%; P<0.001), arthritis (I2 = 92.4%; P<0.001), osteoporosis (I2 = 82.1%; P = 0.001), tumor (I2 = 79.9%; P<0.001), and MGD (I2 = 85.2%; P = 0.001), while no significant heterogeneity for gout (I2 = 41.8%; P = 0.126), eczema (I2 = 0.0%; P = 0.609), and systemic disease (I2 = 0.0%; P = 0.007) was observed. The pooled conclusions for the association of gout, migraines, arthritis, osteoporosis, and tumor with the risk of DES were robust after sequentially removing individual studies (S3 File). Although the results of subgroup analyses were consistent with the overall analysis in most subsets, gout, osteoporosis, and tumor were not associated with risk of DES if pooled studies were performed in Eastern countries. There was no significant publication bias for gout (P-value for Egger: 0.902; P-value for Begg: 0.707), migraines (P-value for Egger: 0.249; P-value for Begg: 0.806), arthritis (P-value for Egger: 0.169; P-value for Begg: 0.360), osteoporosis (P-value for Egger: 0.137; P-value for Begg: 0.308), and tumor (P-value for Egger: 0.721; P-value for Begg: 1.000) (S4 File).

Discussion

This systematic review and meta-analysis was based on published observational studies explored potential risk factors for DES and included 493,630 individuals from 48 studies. We found that risk factors for DES included older age, female sex, other race, VDT use, cataract surgery, contact lens wear, pterygium, glaucoma, eye surgery, depression, PTSD, sleep apnea, asthma, allergy, hypertension, DM, CVD, stroke, rosacea, thyroid disease, gout, migraines, arthritis, osteoporosis, tumor, eczema, and systemic disease. Moreover, country of origin could affect association for age, sex, education level, dyslipidemia, smoking, contact lens wear, age-related maculopathy, eye surgery, depression, sleep apnea, asthma, hypertension, DM, rosacea, COPD, migraines, and osteoporosis regarding the risk of DES.

This current study primarily identified potential risk factors for DES, although several factors have already been demonstrated in individual studies. Prior studies have demonstrated that a 5-year incidence of dry eye rises from 10.7% to 17.9% alongside increasing age [72]. A potential reason could be the reduction of tear secretion with biological aging [2, 73]. Moreover, the sex difference in DES could be explained by various hormonal effects on the ocular surface and lacrimal gland [8]. The potential impact for VDT use could be due to increasing rates of incomplete blinks and accelerated evaporation of the tear film [74]. The increased risk of DES after cataract surgery could be explained by cataract surgery inducing tear film dysfunction [75]. The role of contact lens wear on DES could be explained in that placing a lens on the eye could cause disturbance of the tear film [76]. DES could be considered as a precipitating factor of primary pterygium [77]. The treatment of glaucoma could alter the surface of the eye through disturbing tear secretion, which could affect the progression of DES [78]. Studies have already found that open eye surgery could affect altered tear secretion in nearly 91% of patients, thus playing an important role in the risk of DES [79]. The potential role of depression and PTSD could be explained by the dysregulation of neuropeptides coupled with serotonin in human tears and serotonin receptors in human conjunctivae [80]. Sleep apnea is significantly associated with neuropathic pain, which could induce the progression of dry eye syndrome [81]. The role of asthma and allergy on the risk of DES could be explained by antihistaminic and anti-inflammatory agents used for asthma and allergy treatment, which could potentially cause an elevated risk of DES [82].

This study found that hypertension and DM were associated with an increased risk of DES, which was consistent with the results of a prior meta-analysis [83]. A potential reason for this could be hypertension was not direct affect the risk of DES, while the use of anti-hypertensive medication could increase the risk of DES [33]. In addition, the risk of DES were not increased in hypertensive patients treated with anti-hypertensive medications, such as Angiotension Converting Enzyme inhibitors might play a protective role on the risk of DES [34]. Moreover, DM could induce a decrease in corneal sensation and tear production, impaired metabolic activity, and loss of cytoskeletal structure, all of which could affect the progression of DES [84]. The underlying therapies for CVD, stroke, and tumor could be regarded as disposing of factors for DES [25]. Rosacea is a well known risk factor for DES due to is pro-inflammatory effects that induce meibomian gland dysfunction and evaporative DES [85]. Studies have already found that thyroid disease is significantly related to ocular surface damage, eyelid retraction/impaired Bell’s phenomenon, and reduced tear production [86]. Gout was associated with the tophaceous deposits in different locations of the eye, including eyelids, conjunctiva, cornea, iris, sclera, and orbit, a similar reason could explain the role of arthritis on DES [87]. The role of migraines on DES could be explained by an inflammatory status in migraine patients potentially activating inflammation in the eyes [88]. The inflammation and hormone imbalance caused by osteoporosis could explain an elevated risk of DES [89]. The treatment for eczema and systemic disease could cause an elevated risk of DES [90].

Our study found that potential associations for age, sex, education level, dyslipidemia, smoking, contact lens wear, age-related maculopathy, eye surgery, depression, sleep apnea, asthma, hypertension, DM, rosacea, COPD, migraines, and osteoporosis with the risk of DES could be affected by country of origin. The disease distribution for DES is different in Eastern and Western countries, and the health policy in various countries could further affect the progression of DES. Moreover, environmental, dietary, and lifestyle factors among various countries differ, which could affect the progression of DES [91, 92].

Several shortcomings of this study should be acknowledged. First, this study contained cross-sectional, retrospective, and prospective observational studies, and the causality relationships between risk factors and DES could not available. Second, the heterogeneity for most risk factors was substantial, which was not fully explained by sensitivity and subgroup analyses. Third, the comorbidity and underlying therapies for individuals were not fully adjusted, which could affect the progression of DES. Fourth, the cutoff value for age, and definition for systemic disease, eye surgery, and DES are different across included studies, which could induce potential uncontrolled biases. Fifth, the climate type could affect the progression of DES, and nearly all of included studies did not address the climate type. Sixth, the analysis based on published articles, the gray literature and unpublished data were not available, and the publication bias was inevitable. Seventh, the analysis using the pooled data, and the detailed analyses were restricted. Finally, this study was not registered in PROSPERO, and the transparency was restricted.

Conclusions

This study identified comprehensive risk factors for DES, including older age, female sex, other race, VDT use, cataract surgery, contact lens wear, pterygium, glaucoma, eye surgery, depression, PTSD, sleep apnea, asthma, allergy, hypertension, DM, CVD, stroke, rosacea, thyroid disease, gout, migraines, arthritis, osteoporosis, tumor, eczema, and systemic disease. Further large-scale prospective cohort studies should be performed to verify the results of this study.

Supporting information

S1 Checklist. PRISMA 2020 checklist.

(PDF)

Click here for additional data file. (118.1KB, pdf)
S1 Table. Quality scores of prospective cohort studies using Newcastle-Ottawa Scale.

(DOCX)

Click here for additional data file. (20.7KB, docx)
S1 File. Search strategy in PubMed.

(DOCX)

Click here for additional data file. (11KB, docx)
S2 File. Forest plots for the risk factors of dry eye syndrome.

(DOCX)

Click here for additional data file. (3.1MB, docx)
S3 File. Sensitivity analyses for the risk factors of dry eye syndrome.

(DOCX)

Click here for additional data file. (86.5MB, docx)
S4 File. Funnel plots for the risk factors of dry eye syndrome.

(DOCX)

Click here for additional data file. (94.5MB, docx)

Abbreviations

CI

confidence interval

COPD

chronic obstructive pulmonary disease

CVD

cardiovascular disease

DES

dry eye syndrome

DM

diabetes mellitus

HR

hazard ratio

MGD

meibomian gland dysfunction

NOS

Newcastle-Ottawa Scale

OR

odds ratio

PTSD

post-traumatic stress disorder

RR

relative risk

VDT

visual display terminal

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276–283. doi: 10.1016/j.jtos.2017.05.008 [DOI] [PubMed] [Google Scholar]
  • 2.Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–412. doi: 10.2147/opth.s5555 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Uchino M, Schaumberg D. Dry Eye Disease: Impact on Quality of Life and Vision. Curr Ophthalmol Rep 2013;1:51–7. doi: 10.1007/s40135-013-0009-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Findlay Q, Reid K. Dry eye disease: when to treat and when to refer. Aust Prescr 2018; 41:160–3. doi: 10.18773/austprescr.2018.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res 2011;6:192–8. [PMC free article] [PubMed] [Google Scholar]
  • 6.Jain S, Bhavsar A, Bhavsar S. A review on recent advances in dry eye: Pathogenesis and management. Oman J Opthalmol 2011;4:50. doi: 10.4103/0974-620X.83653 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IÖ, Evans AM, et al. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. Am J Ophthalmol. 2019;202:47–54. doi: 10.1016/j.ajo.2019.01.026 [DOI] [PubMed] [Google Scholar]
  • 8.Song P, Xia W, Wang M, Chang X, Wang J, Jin S, et al. Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: a systematic review and meta-analysis. J Glob Health. 2018;8:020503. doi: 10.7189/jogh.08.020503 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93–107. doi: 10.1016/s1542-0124(12)70082-4 [DOI] [PubMed] [Google Scholar]
  • 10.Courtin R, Pereira B, Naughton G, Chamoux A, Chiambaretta F, Lanhers C, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. BMJ Open. 2016;6:e009675. doi: 10.1136/bmjopen-2015-009675 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ahn J, Ryu SJ, Song J, Kim HR. Shift Work and Dry Eye Disease in the Korean Working Population: A Population-Based Cross-Sectional Study. Int J Environ Res Public Health. 2021;18:5492. doi: 10.3390/ijerph18105492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liu J, Dong Y, Wang Y. Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis. Acta Ophthalmol. 2020;98:749–754. doi: 10.1111/aos.14470 [DOI] [PubMed] [Google Scholar]
  • 13.Yoo TK, Oh E. Diabetes mellitus is associated with dry eye syndrome: a meta-analysis. Int Ophthalmol. 2019;39:2611–2620. doi: 10.1007/s10792-019-01110-y [DOI] [PubMed] [Google Scholar]
  • 14.Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097. doi: 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7:e1020–e1030 doi: 10.1016/S2214-109X(19)30255-4 [DOI] [PubMed] [Google Scholar]
  • 16.Wells G, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2009. Available: http://www.ohri.ca/programs/clinical_epidemiology /oxford.htm. [Google Scholar]
  • 17.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–88. doi: 10.1016/0197-2456(86)90046-2 [DOI] [PubMed] [Google Scholar]
  • 18.Ades AE, Lu G, Higgins JP. The interpretation of random-effects metaanalysis in decision models. Med Decis Making. 2005; 25: 646–54. doi: 10.1177/0272989X05282643 [DOI] [PubMed] [Google Scholar]
  • 19.Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration: 2008; chap 9. [Google Scholar]
  • 20.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. doi: 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull. 1999;47:15–7. [Google Scholar]
  • 22.Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003; 326: 219. doi: 10.1136/bmj.326.7382.219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. doi: 10.1136/bmj.315.7109.629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088–1101. [PubMed] [Google Scholar]
  • 25.Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–8. doi: 10.1001/archopht.118.9.1264 [DOI] [PubMed] [Google Scholar]
  • 26.Lee AJ, Lee J, Saw SM, Gazzard G, Koh D, Widjaja D, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002;86:1347–51. doi: 10.1136/bjo.86.12.1347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2003;31:229–32. doi: 10.1046/j.1442-9071.2003.00634.x [DOI] [PubMed] [Google Scholar]
  • 28.Sahai A, Malik P. Dry eye: prevalence and attributable risk factors in a hospital-based population. Indian J Ophthalmol. 2005;53:87–91. doi: 10.4103/0301-4738.16170 [DOI] [PubMed] [Google Scholar]
  • 29.Nichols JJ, Sinnott LT. Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye. Invest Ophthalmol Vis Sci. 2006;47:1319–28. doi: 10.1167/iovs.05-1392 [DOI] [PubMed] [Google Scholar]
  • 30.Uchino M, Schaumberg DA, Dogru M, Uchino Y, Fukagawa K, Shimmura S, et al. Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology. 2008;115:1982–8. doi: 10.1016/j.ophtha.2008.06.022 [DOI] [PubMed] [Google Scholar]
  • 31.Lu P, Chen X, Liu X, Yu L, Kang Y, Xie Q, et al. Dry eye syndrome in elderly Tibetans at high altitude: a population-based study in China. Cornea. 2008;27:545–51. doi: 10.1097/ICO.0b013e318165b1b7 [DOI] [PubMed] [Google Scholar]
  • 32.Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009;127:763–8. doi: 10.1001/archophthalmol.2009.103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol. 2009;16: 15–21. doi: 10.1080/09286580802228509 [DOI] [PubMed] [Google Scholar]
  • 34.Jie Y, Xu L, Wu YY, Jonas JB. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. Eye (Lond). 2009;23:688–93. doi: 10.1038/sj.eye.6703101 [DOI] [PubMed] [Google Scholar]
  • 35.Guo B, Lu P, Chen X, Zhang W, Chen R. Prevalence of dry eye disease in Mongolians at high altitude in China: the Henan eye study. Ophthalmic Epidemiol. 2010;17:234–41. doi: 10.3109/09286586.2010.498659 [DOI] [PubMed] [Google Scholar]
  • 36.Kim KW, Han SB, Han ER, Woo SJ, Lee JJ, Yoon JC, et al. Association between depression and dry eye disease in an elderly population. Invest Ophthalmol Vis Sci. 2011;52: 7954–8. doi: 10.1167/iovs.11-8050 [DOI] [PubMed] [Google Scholar]
  • 37.Uchino M, Nishiwaki Y, Michikawa T, Shirakawa K, Kuwahara E, Yamada M, et al. Prevalence and risk factors of dry eye disease in Japan: Koumi study. Ophthalmology. 2011; 118:2361–7. doi: 10.1016/j.ophtha.2011.05.029 [DOI] [PubMed] [Google Scholar]
  • 38.Galor A, Feuer W, Lee DJ, Florez H, Carter D, Pouyeh B, et al. Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population. Am J Ophthalmol. 2011;152:377–384.e2. doi: 10.1016/j.ajo.2011.02.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhang Y, Chen H, Wu X. Prevalence and risk factors associated with dry eye syndrome among senior high school students in a county of Shandong Province, China. Ophthalmic Epidemiol. 2012;19:226–30. doi: 10.3109/09286586.2012.670742 [DOI] [PubMed] [Google Scholar]
  • 40.Wang TJ, Wang IJ, Hu CC, Lin HC. Comorbidities of dry eye disease: a nationwide population-based study. Acta Ophthalmol. 2012;90:663–8. doi: 10.1111/j.1755-3768.2010.01993.x [DOI] [PubMed] [Google Scholar]
  • 41.Uchino M, Yokoi N, Uchino Y, Dogru M, Kawashima M, Komuro A, et al. Prevalence of dry eye disease and its risk factors in visual display terminal users: the Osaka study. Am J Ophthalmol. 2013;156:759–66. doi: 10.1016/j.ajo.2013.05.040 [DOI] [PubMed] [Google Scholar]
  • 42.Vehof J, Kozareva D, Hysi PG, Hammond CJ. Prevalence and risk factors of dry eye disease in a British female cohort. Br J Ophthalmol. 2014;98:1712–7. doi: 10.1136/bjophthalmol-2014-305201 [DOI] [PubMed] [Google Scholar]
  • 43.Ahn JM, Lee SH, Rim TH, Park RJ, Yang HS, Kim TI, et al. Prevalence of and risk factors associated with dry eye: the Korea National Health and Nutrition Examination Survey 2010–2011. Am J Ophthalmol. 2014;158:1205–1214.e7. doi: 10.1016/j.ajo.2014.08.021 [DOI] [PubMed] [Google Scholar]
  • 44.Moon JH, Lee MY, Moon NJ. Association between video display terminal use and dry eye disease in school children. J Pediatr Ophthalmol Strabismus. 2014;51:87–92. doi: 10.3928/01913913-20140128-01 [DOI] [PubMed] [Google Scholar]
  • 45.Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157:799–806. doi: 10.1016/j.ajo.2013.12.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Chen HY, Lin CL, Tsai YY, Kao CH. Association between Glaucoma Medication Usage and Dry Eye in Taiwan. Optom Vis Sci. 2015;92:e227–32. doi: 10.1097/OPX.0000000000000667 [DOI] [PubMed] [Google Scholar]
  • 47.Yang WJ, Yang YN, Cao J, Man ZH, Yuan J, Xiao X, et al. Risk Factors for Dry Eye Syndrome: A Retrospective Case-Control Study. Optom Vis Sci. 2015;92:e199–205. doi: 10.1097/OPX.0000000000000541 [DOI] [PubMed] [Google Scholar]
  • 48.Tan LL, Morgan P, Cai ZQ, Straughan RA. Prevalence of and risk factors for symptomatic dry eye disease in Singapore. Clin Exp Optom. 2015;98:45–53. doi: 10.1111/cxo.12210 [DOI] [PubMed] [Google Scholar]
  • 49.Shah S, Jani H. Prevalence and associated factors of dry eye: Our experience in patients above 40 years of age at a Tertiary Care Center. Oman J Ophthalmol. 2015;8: 151–6. doi: 10.4103/0974-620X.169910 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Olaniyan SI, Fasina O, Bekibele CO, Ogundipe AO. Dry eye disease in an adult population in South-West Nigeria. Cont Lens Anterior Eye. 2016;39:359–64. doi: 10.1016/j.clae.2016.06.008 [DOI] [PubMed] [Google Scholar]
  • 51.Alshamrani AA, Almousa AS, Almulhim AA, Alafaleq AA, Alosaimi MB, Alqahtani AM, et al. Prevalence and Risk Factors of Dry Eye Symptoms in a Saudi Arabian Population. Middle East Afr J Ophthalmol. 2017;24:67–73. doi: 10.4103/meajo.MEAJO_281_16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017;182:90–98. doi: 10.1016/j.ajo.2017.06.033 [DOI] [PubMed] [Google Scholar]
  • 53.Man REK, Veerappan AR, Tan SP, Fenwick EK, Sabanayagam C, Chua J, et al. Incidence and risk factors of symptomatic dry eye disease in Asian Malays from the Singapore Malay Eye Study. Ocul Surf. 2017;15:742–748. doi: 10.1016/j.jtos.2017.04.004 [DOI] [PubMed] [Google Scholar]
  • 54.Gong YY, Zhang F, Zhou J, Li J, Zhang GH, Wang JL, et al. Prevalence of Dry Eye in Uyghur and Han Ethnic Groups in Western China. Ophthalmic Epidemiol. 2017;24:181–187. doi: 10.1080/09286586.2016.1263996 [DOI] [PubMed] [Google Scholar]
  • 55.Graue-Hernández EO, Serna-Ojeda JC, Estrada-Reyes C, Navas A, Arrieta-Camacho J, Jiménez-Corona A. Dry eye symptoms and associated risk factors among adults aged 50 or more years in Central Mexico. Salud Publica Mex. 2018;60:520–527. doi: 10.21149/9024 [DOI] [PubMed] [Google Scholar]
  • 56.Millán A, Viso E, Gude F, Parafita-Fernández A, Moraña N, Rodríguez-Ares MT. Incidence and Risk Factors of Dry Eye in a Spanish Adult Population: 11-Year Follow-Up From the Salnés Eye Study. Cornea. 2018;37:1527–1534. doi: 10.1097/ICO.0000000000001713 [DOI] [PubMed] [Google Scholar]
  • 57.Iglesias E, Sajnani R, Levitt RC, Sarantopoulos CD, Galor A. Epidemiology of Persistent Dry Eye-Like Symptoms After Cataract Surgery. Cornea. 2018;37:893–898. doi: 10.1097/ICO.0000000000001491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Ferrero A, Alassane S, Binquet C, Bretillon L, Acar N, Arnould L, et al. Dry eye disease in the elderly in a French population-based study (the Montrachet study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases): Prevalence and associated factors. Ocul Surf. 2018;16:112–119. doi: 10.1016/j.jtos.2017.09.008 [DOI] [PubMed] [Google Scholar]
  • 59.Shehadeh-Mashor R, Mimouni M, Shapira Y, Sela T, Munzer G, Kaiserman I. Risk Factors for Dry Eye After Refractive Surgery. Cornea. 2019;38:1495–1499. doi: 10.1097/ICO.0000000000002152 [DOI] [PubMed] [Google Scholar]
  • 60.Zhang S, Hong J. Risk Factors for Dry Eye in Mainland China: A Multi-Center Cross-Sectional Hospital-Based Study. Ophthalmic Epidemiol. 2019;26:393–399. doi: 10.1080/09286586.2019.1632905 [DOI] [PubMed] [Google Scholar]
  • 61.Yasir ZH, Chauhan D, Khandekar R, Souru C, Varghese S. Prevalence and Determinants of Dry Eye Disease among 40 Years and Older Population of Riyadh (Except Capital), Saudi Arabia. Middle East Afr J Ophthalmol. 2019;26:27–32. doi: 10.4103/meajo.MEAJO_194_18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Arita R, Mizoguchi T, Kawashima M, Fukuoka S, Koh S, Shirakawa R, et al. Meibomian Gland Dysfunction and Dry Eye Are Similar but Different Based on a Population-Based Study: The Hirado-Takushima Study in Japan. Am J Ophthalmol. 2019;207:410–418. doi: 10.1016/j.ajo.2019.02.024 [DOI] [PubMed] [Google Scholar]
  • 63.Hyon JY, Yang HK, Han SB. Association between Dry Eye Disease and Psychological Stress among Paramedical Workers in Korea. Sci Rep. 2019;9:3783. doi: 10.1038/s41598-019-40539-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Ben-Eli H, Aframian DJ, Ben-Chetrit E, Mevorach D, Kleinstern G, Paltiel O, et al. Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren’s Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study. J Immunol Res. 2019;2019: 9060842. doi: 10.1155/2019/9060842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Yu D, Deng Q, Wang J, Chang X, Wang S, Yang R, et al. Air Pollutants are associated with Dry Eye Disease in Urban Ophthalmic Outpatients: a Prevalence Study in China. J Transl Med. 2019;17:46. doi: 10.1186/s12967-019-1794-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Rossi GCM, Scudeller L, Bettio F, Pasinetti GM, Bianchi PE. Prevalence of dry eye in video display terminal users: a cross-sectional Caucasian study in Italy. Int Ophthalmol. 2019; 39:1315–1322. doi: 10.1007/s10792-018-0947-6 [DOI] [PubMed] [Google Scholar]
  • 67.Wang MTM, Vidal-Rohr M, Muntz A, Diprose WK, Ormonde SE, Wolffsohn JS, et al. Systemic risk factors of dry eye disease subtypes: A New Zealand cross-sectional study. Ocul Surf. 2020;18:374–380. doi: 10.1016/j.jtos.2020.04.003 [DOI] [PubMed] [Google Scholar]
  • 68.Shanti Y, Shehada R, Bakkar MM, Qaddumi J. Prevalence and associated risk factors of dry eye disease in 16 northern West bank towns in Palestine: a cross-sectional study. BMC Ophthalmol. 2020;20:26. doi: 10.1186/s12886-019-1290-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Hanyuda A, Sawada N, Uchino M, Kawashima M, Yuki K, Tsubota K, et al. Physical inactivity, prolonged sedentary behaviors, and use of visual display terminals as potential risk factors for dry eye disease: JPHC-NEXT study. Ocul Surf. 2020;18:56–63. doi: 10.1016/j.jtos.2019.09.007 [DOI] [PubMed] [Google Scholar]
  • 70.Alkabbani S, Jeyaseelan L, Rao AP, Thakur SP, Warhekar PT. The prevalence, severity, and risk factors for dry eye disease in Dubai—a cross sectional study. BMC Ophthalmol. 2021;21:219. doi: 10.1186/s12886-021-01978-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Vehof J, Snieder H, Jansonius N, Hammond CJ. Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in the Netherlands. Ocul Surf. 2021;19:83–93. doi: 10.1016/j.jtos.2020.04.005 [DOI] [PubMed] [Google Scholar]
  • 72.Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol. 2004;122:369–73. doi: 10.1001/archopht.122.3.369 [DOI] [PubMed] [Google Scholar]
  • 73.Gilbard JP. Human tear film electrolyte concentrations in health and dry-eye disease. Int Ophthalmol Clin. 1994;34:27–36. doi: 10.1097/00004397-199403410-00005 [DOI] [PubMed] [Google Scholar]
  • 74.Cardona G, García C, Serés C, Vilaseca M, Gispets J. Blink rate, blink amplitude, and tear film integrity during dynamic visual display terminal tasks. Curr Eye Res. 2011;36: 190–7. doi: 10.3109/02713683.2010.544442 [DOI] [PubMed] [Google Scholar]
  • 75.Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007;26:S16–20. doi: 10.1097/ICO.0b013e31812f67ca [DOI] [PubMed] [Google Scholar]
  • 76.Begley CG, Caffery B, Nichols KK, Chalmers R. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci. 2000;77:40–6. doi: 10.1097/00006324-200001000-00012 [DOI] [PubMed] [Google Scholar]
  • 77.Petraevskiĭ AV, Trishkin KS. [Pathogenetic relationship between pterygium and dry eye syndrome (clinical and cytological study)]. Vestn Oftalmol. 2014;130:52–6. Russian. [PubMed] [Google Scholar]
  • 78.Bulat N, Cuşnir VV, Procopciuc V, Cușnir V, Cuşnir NV. Diagnosing the Dry Eye Syndrome in modern society and among patients with glaucoma: a prospective study. Rom J Ophthalmol. 2020;64:35–42. [PMC free article] [PubMed] [Google Scholar]
  • 79.Samoilă O, Stan C, Vişan O, Crăciun A, Dican L, Mera M. Influenţa intervenţiilor chirurgicale pe gldb deschis asupra secreţiei lacrimale [The influence of ocular surgery for lacrimal secretion]. Oftalmologia. 2007;51:81–5. Romanian. [PubMed] [Google Scholar]
  • 80.Galor A, Feuer W, Lee DJ, Florez H, Faler AL, Zann KL, et al. Depression, post-traumatic stress disorder, and dry eye syndrome: a study utilizing the national United States Veterans Affairs administrative database. Am J Ophthalmol. 2012;154:340–346.e2. doi: 10.1016/j.ajo.2012.02.009 [DOI] [PubMed] [Google Scholar]
  • 81.Ong ES, Alghamdi YA, Levitt RC, McClellan AL, Lewis G, Sarantopoulos CD, et al. Longitudinal Examination of Frequency of and Risk Factors for Severe Dry Eye Symptoms in US Veterans. JAMA Ophthalmol. 2017;135:116–123. doi: 10.1001/jamaophthalmol.2016.4925 [DOI] [PubMed] [Google Scholar]
  • 82.Bielory L. Ocular toxicity of systemic asthma and allergy treatments. Curr Allergy Asthma Rep. 2006;6:299–305. doi: 10.1007/s11882-006-0063-y [DOI] [PubMed] [Google Scholar]
  • 83.Tang YL, Cheng YL, Ren YP, Yu XN, Shentu XC. Metabolic syndrome risk factors and dry eye syndrome: a Meta-analysis. Int J Ophthalmol. 2016;9:1038–45. doi: 10.18240/ijo.2016.07.17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Xu L, You QS, Jonas JB. Prevalence of alcohol consumption and risk of ocular diseases in a general population: the Beijing Eye Study. Ophthalmology. 2009;116:1872–9. doi: 10.1016/j.ophtha.2009.04.014 [DOI] [PubMed] [Google Scholar]
  • 85.Woo YR, Cho M, Ju HJ, Bae JM, Cho SH, Lee JD, et al. Ocular Comorbidities in Rosacea: A Case-Control Study Based on Seven Institutions. J Clin Med. 2021;10:2897. doi: 10.3390/jcm10132897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Eckstein AK, Finkenrath A, Heiligenhaus A, Renzing-Köhler K, Esser J, Krüger C, et al. Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand. 2004;82:291–7. doi: 10.1111/j.1395-3907.2004.00268.x [DOI] [PubMed] [Google Scholar]
  • 87.Sharon Y, Schlesinger N. Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. Curr Rheumatol Rep. 2016;18:37. doi: 10.1007/s11926-016-0586-8 [DOI] [PubMed] [Google Scholar]
  • 88.Koktekir BE, Celik G, Karalezli A, Kal A. Dry eyes and migraines: is there really a correlation? Cornea. 2012;31:1414–6. doi: 10.1097/ICO.0b013e318247ec2a [DOI] [PubMed] [Google Scholar]
  • 89.Jeng YT, Lin SY, Hu HY, Lee OK, Kuo LL. Osteoporosis and dry eye syndrome: A previously unappreciated association that may alert active prevention of fall. PLoS One. 2018; 13:e0207008. doi: 10.1371/journal.pone.0207008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Goulden V, Layton AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol. 1994;131:360–3. doi: 10.1111/j.1365-2133.1994.tb08524.x [DOI] [PubMed] [Google Scholar]
  • 91.Klocek P, Klocek M, Jeśman C. [Assessment of the incidence of dry eye syndrome symptoms in Military Police soldiers serving outside the country]. Pol Merkur Lekarski. 2020; 48:82–86. [PubMed] [Google Scholar]
  • 92.Youn JS, Seo JW, Park W, Park S, Jeon KJ. Prediction Model for Dry Eye Syndrome Incidence Rate Using Air Pollutants and Meteorological Factors in South Korea: Analysis of Sub-Region Deviations. Int J Environ Res Public Health. 2020;17:4969. doi: 10.3390/ijerph17144969 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Michael Mimouni

19 Jan 2022

PONE-D-21-35192Identified risk factors for dry eye syndrome: A systematic review and meta-analysisPLOS ONE

Dear Dr. Wei,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 05 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Mimouni

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please confirm that you have included all items recommended in the PRISMA checklist including:

- the full electronic search strategy used to identify studies with all search terms and limits for at least one database.

- a Supplemental file of the results of the individual components of the quality assessment, not just the overall score, for each study included.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Manuscript ID: PONE-D-21-35192

Title: Identified risk factors for dry eye syndrome: A systematic review and meta-analysis

The authors report on a meta-analysis of an important topic – risk factors for dry eye syndrome. I thank the authors for their persistence with this large and complex analysis, however their analysis is limited by multiple methodologic and reporting concerns. The quality of evidence used to make these conclusions is also suspect, given the large proportion of cross-sectional studies that are susceptible to recall bias and variability in the adjustment for confounding factors across studies.

Specific comments are provided below:

1. Methods, Abstract: The model used for meta-analysis should be specified, as well as the inclusion and exclusion criteria for study selection.

2. Conclusion, Abstract: The authors should elaborate on their conclusion section to discuss the implications of their findings and/or areas for future research.

3. Introduction: expand on the risk factor ‘visual display terminal’ for readers who may be unfamiliar with this term.

4. Introduction: “However, the presence of other comorbidities and individuals’ characteristics on the risk of DES were not illustrated.” The authors should specify that there is conflicting or negative evidence for these other characteristics as opposed to these being uninvestigated characteristics.

5. Methods: “The following search terms were used: ("Dry Eye Syndromes"[Mesh]) AND "Risk Factors"[Mesh].” The search strategy provided by the authors is quite simplistic and does not account for other formulations of the same concept found in these major databases. No text-based searches are also integrated to ensure maximal literature coverage.

6. Methods: Did the authors investigate the gray literature as part of this systematic review?

7. Methods: specify with initials the authors that independently screened studies and extracted data.

8. Methods: the authors note that all studies reporting on dry eye risk factors were considered. Were interventional studies assessing the impact of dry eye treatment also included?

9. Methods: was the systematic review prospectively registered in the PROSPERO database?

10. Methods: The authors note that studies which assessed risk factors in at least 3 cohorts were included. Some studies assessing risk factors for dry eye may have only focused on one risk factor and would therefore be excluded under the current methodology. This overly restrictive inclusion criterion seems arbitrary and unwarranted.

11. Methods: Was a GRADE evaluation performed to assess the certainty of findings?

12. Methods: “Identified risk factors for DES were analyzed based on the effect estimate, with its 95% CI, in 99 individual studies.” What effect estimate was considered? Elaborate on the exact methods used. For continuous variables like age, how were they categorized into binary groups for analysis?

13. Methods: Only one subgroup analysis based on country was considered in the analysis. There are likely multiple potential confounders in this analysis that can be investigated for using subgroup analysis, including severity of dry eye, individuals with dry eye secondary to another condition eg Sjogren’s, evaporative vs aqueous deficient dry eye, study design, etc.

14. Methods, statistical analysis: specify the measure of association used to report the results – ie odds ratio with 95% confidence interval.

15. Results: what proportion of results of studies was derived from a multivariable analysis that controlled for confounding parameters versus a univariable analysis?

16. Results: provide more information in the study characteristics section on the type and severity of dry eye, observational vs interventional studies, the recency of publication, the pooled gender and age distribution, and other relevant baseline parameters for this analysis.

17. Results: expand on the results of the risk of bias assessment – what was the most frequent reason for downgrading the risk of bias?

18. Results: It would be important to clarify the definition of DES used in the analysis, and whether this definition was different across included studies.

19. Results: When reporting the results for each risk factor, it would be helpful to provide the proportion of the characteristic in the DES vs no DES groups, e.g. mean age, % female, race distribution, etc.

20. Results: For endpoints that had significant statistical heterogeneity, was the heterogeneity changed in the subgroup analysis?

21. Results: For glaucoma as a risk factor, it would important to clarify the therapy received, as this likely impacts the risk of DES.

22. Results: For eye surgery as a risk factor, clarify what type of surgeries were considered.

23. Results: In the reporting of the various risk factors, certain risk factors are grouped with others in the same paragraph. It is unclear how the various risk factors were grouped. It would be helpful to add subheadings to clarify this.

24. Results: “systemic disease” as a risk factor is not helpful or clinically relevant. This needs to be specified as to which specific systemic disease was considered or otherwise removed from the analysis.

25. Discussion: “we noted that other races versus white race were associated with an increased risk of DES, which is significantly related to the climate type.” Is race a risk factor independent of climate type? Elaborate on how climate type mediated this effect.

26. Discussion: “anti-hypertensive medication could increase the risk of DES”. What is the mechanism of this association?

27. Discussion: “The role of rosacea could be explained by its significant relation to corneal neovascularization and perforation, which could induce vision loss and ocular comorbidities.[85]” This relation is poorly described. Rosacea is a well known risk factor for DES due to is pro-inflammatory effects that induce meibomian gland dysfunction and evaporative DES.

28. Discussion: “Studies have already found that thyroid disease is significantly related to ocular surface damage, elevated lip aperture” – ‘elevated lip aperture’ should read ‘eyelid retraction’

29. Discussion: a major limitation is that the impact of confounding variables is unaddressed by certain studies, and multivariable associations were only reported for certain risk factors. Given the large proportion of cross-sectional studies, recall bias is likely a significant issue in these results.

30. Figure 2: p-value column – unsure why the p-values displayed in this way, as if multiple numbers are written on top of one another? What is the significance of the blue/gray background behind the forest plot for each endpoint?

Reviewer #2: This is a very well written meta-analysis regarding the potential risk factors for dry eye syndrome. Nevertheless, risk factors for DES are widely known, therefore, my question to the authors is:

In which way this meta analysis contributes to the literature already published regarding the risk factors for DES.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 19;17(8):e0271267. doi: 10.1371/journal.pone.0271267.r002

Author response to Decision Letter 0

21 Feb 2022

Point-By-Point Response

Journal Requirements:

Question 1: Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Thanks for this suggestion, and the style of manuscript have already updated meets PLOS ONE's style requirements.

Question 2: Please confirm that you have included all items recommended in the PRISMA checklist including:

- the full electronic search strategy used to identify studies with all search terms and limits for at least one database.

- a Supplemental file of the results of the individual components of the quality assessment, not just the overall score, for each study included.

Response: Thanks for this suggestion, and the full electronic search strategy in PubMed have already listed in Methods section. Moreover, the individual components of the quality assessment for each study have already added in Supplementary file.

Question 3: In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: Thanks for this suggestion, and the Data Availability statement have already changed into: “Data availability: All relevant data are within the paper and its Supporting information files.”

Question 4: PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

Response: Thanks for this suggestion, and the ORCID ID for the corresponding author will submit in Editorial Manager when upload the revised manuscript.

Question 5: Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: Thanks for this suggestion, and the captions for your Supporting Information files have already added at the end of manuscript.

Reviewer #1:

General comments: The authors report on a meta-analysis of an important topic - risk factors for dry eye syndrome. I thank the authors for their persistence with this large and complex analysis, however their analysis is limited by multiple methodologic and reporting concerns. The quality of evidence used to make these conclusions is also suspect, given the large proportion of cross-sectional studies that are susceptible to recall bias and variability in the adjustment for confounding factors across studies.

Response: As behalf of all co-authors, I would like to appreciate this referee due to thoughtful comments proposed by the peer review. After we revised the manuscript, those significant issues could be changed. Moreover, this comment have already addressed in Limitation section.

Question 1: Methods, Abstract: The model used for meta-analysis should be specified, as well as the inclusion and exclusion criteria for study selection.

Response: Thanks for this suggestion, and the methods in abstract have already changed into: “PubMed, Embase, and the Cochrane library were systematically searched for studies investigated the risk factors for dry eye syndrome from their inception until September 2021. The odds ratio (OR) with 95% confidence interval (CI) was calculated using the random-effects model.”

Question 2: Conclusion, Abstract: The authors should elaborate on their conclusion section to discuss the implications of their findings and/or areas for future research.

Response: Thanks for this suggestion, and the conclusion in abstract have already changed into: “This study reported the comprehensive risk factors for dry eye syndrome, including demographic information, clinical characteristics, and comorbidities.”

Question 3: Introduction: expand on the risk factor ‘visual display terminal’ for readers who may be unfamiliar with this term.

Response: Thanks for this suggestion, and the following sentence have already added in the revised manuscript: “Moreover, the occupational risk factor of visual display terminal (VDT) use was related to the progression of DES, which could explained by decreases blink rate and increases the proportion of incomplete blinks could causing the increased exposure of the ocular surface to the environment.”

Question 4: Introduction: “However, the presence of other comorbidities and individuals’ characteristics on the risk of DES were not illustrated.” The authors should specify that there is conflicting or negative evidence for these other characteristics as opposed to these being uninvestigated characteristics.

Response: Thanks for this suggestion, and this sentence have already changed into: “However, whether the comorbidities of individuals could affect the risk of DES remained controversial. ”

Question 5: Methods: “The following search terms were used: ("Dry Eye Syndromes"[Mesh]) AND "Risk Factors"[Mesh].” The search strategy provided by the authors is quite simplistic and does not account for other formulations of the same concept found in these major databases. No text-based searches are also integrated to ensure maximal literature coverage.

Response: Thanks for this suggestion, and this sentence have already changed into: “PubMed, Embase, and the Cochrane library were systematically searched for eligible studies from their inception until September 2021, and using the following text word or Medical Subject Heading terms: "dry eye syndrome", "dry eye disease", "Keratoconjunctivitis Sicca", "Xerophthalmia", and "Risk Factors".”

Question 6: Methods: Did the authors investigate the gray literature as part of this systematic review?

Response: Thanks for this suggestion, and the following sentences have already added in Limitation section to address this comments: “Fourth, the analysis based on published articles, the gray literature and unpublished data were not available, and the publication bias was inevitable. Finally, the analysis using the pooled data, and the detailed analyses were restricted. ”

Question 7: Methods: specify with initials the authors that independently screened studies and extracted data.

Response: Thanks for this suggestion, and the initials of authors have already added in the revised manuscript for screened studies and extracted data.

Question 8: Methods: the authors note that all studies reporting on dry eye risk factors were considered. Were interventional studies assessing the impact of dry eye treatment also included?

Response: Thanks for this suggestion. The identified risk factors including demographic information, clinical characteristics, and comorbidities, while potential treatments in interventional studies were not included. We have already added the following sentence in Methods section: “Interventional study, animal study, review, and letter to editor was excluded”.

Question 9: Methods: was the systematic review prospectively registered in the PROSPERO database?

Response: Thanks for this suggestion, this study was not registered in the PROSPERO, which have already addressed in Limitation section.

Question 10: Methods: The authors note that studies which assessed risk factors in at least 3 cohorts were included. Some studies assessing risk factors for dry eye may have only focused on one risk factor and would therefore be excluded under the current methodology. This overly restrictive inclusion criterion seems arbitrary and unwarranted.

Response: Thanks for this suggestion. The main findings of this meta-analysis focused on quantitative analysis, and the conclusions obtained from 1 or 2 studies caused the variable of pooled results. Moreover, the screening criteria was referring to the following articles: Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019 Aug;7(8):e1020-e1030. 

Question 11: Methods: Was a GRADE evaluation performed to assess the certainty of findings?

Response: Thanks for this suggestion, and this study contained cross-sectional, retrospective, and prospective observational studies, and the GRADE evaluation was not applied for certainty of findings.

Question 12: Methods: “Identified risk factors for DES were analyzed based on the effect estimate, with its 95% CI, in 99 individual studies.” What effect estimate was considered? Elaborate on the exact methods used. For continuous variables like age, how were they categorized into binary groups for analysis?

Response: Thanks for this suggestion, and this sentence have already changed into: “Identified risk factors for DES were analyzed based on the OR, RR, or HR, with its 95% CI, in individual studies. Then the pooled ORs with 95%CI were calculated using the random-effects model.[16,17]”. Moreover, the categorized for continuous variables were referring to the original articles, which have already addressed in Limitation section.

Question 13: Methods: Only one subgroup analysis based on country was considered in the analysis. There are likely multiple potential confounders in this analysis that can be investigated for using subgroup analysis, including severity of dry eye, individuals with dry eye secondary to another condition eg Sjogren’s, evaporative vs aqueous deficient dry eye, study design, etc.

Response: Thanks for this suggestion. In the planning stage, subgroup analysis should be performed according to study design, the severity of dry eye, and the type of dry eye. However, mostly included studies designed as cross-sectional studies. Moreover, DES was considered as investigated outcome, and the stratified data for the severity of dry eye, and the type of dry eye were not available in mostly included studies.

Question 14: Methods, statistical analysis: specify the measure of association used to report the results - ie odds ratio with 95% confidence interval.

Response: Thanks for this suggestion, and this sentence have already changed into: “Identified risk factors for DES were analyzed based on the OR, RR, or HR, with its 95% CI, in individual studies. Then the pooled ORs with 95%CI were calculated using the random-effects model.[16,17]”

Question 15: Results: what proportion of results of studies was derived from a multivariable analysis that controlled for confounding parameters versus a univariable analysis?

Response: Thanks for this suggestion, and the adjusted factors have already abstracted and listed in Table 1.

Question 16: Results: provide more information in the study characteristics section on the type and severity of dry eye, observational vs interventional studies, the recency of publication, the pooled gender and age distribution, and other relevant baseline parameters for this analysis.

Response: Thanks for this suggestion, the type and severity of DES were available in smaller number of included studies. Moreover, the baseline characteristics of included studies recruited individuals have already listed in Table 1.Finally, several sentences have already added in the second paragraph of Results section.

Question 17: Results: expand on the results of the risk of bias assessment - what was the most frequent reason for downgrading the risk of bias?

Response: Thanks for this suggestion, and the following sentences have already added in the revised manuscript: “The quality of included studies mainly affect by the representativeness of the exposed cohort, and comparability on the basis of the design or analysis. ”

Question 18: Results: It would be important to clarify the definition of DES used in the analysis, and whether this definition was different across included studies.

Response: Thanks for this suggestion, and the definition of DES was based on included studies, and the definition was different among included studies. We have already address this comment in Limitation section.

Question 19: Results: When reporting the results for each risk factor, it would be helpful to provide the proportion of the characteristic in the DES vs no DES groups, e.g. mean age, % female, race distribution, etc.

Response: Thanks for this suggestion. The analysis of this study based on pooled data, and the detailed analyses were restricted, which have already addressed in Limitation section.

Question 20: Results: For endpoints that had significant statistical heterogeneity, was the heterogeneity changed in the subgroup analysis?

Response: Thanks for this suggestion, and the heterogeneity was not fully explained in the sensitivity and subgroup analyses, which have already addressed in Limitation section.

Question 21: Results: For glaucoma as a risk factor, it would important to clarify the therapy received, as this likely impacts the risk of DES.

Response: Thanks for this suggestion. The inclusion criteria was restricted risk factors were reported for ≥ 3 cohorts, and whether the therapies were adjusted have already listed in Table 1.

Question 22: Results: For eye surgery as a risk factor, clarify what type of surgeries were considered.

Response: Thanks for this suggestion. The type of eye surgery was defined based on individual study, and the stratified data based on the type of eye surgery was not available. We have already addressed this comment in Limitation section.

Question 23: Results: In the reporting of the various risk factors, certain risk factors are grouped with others in the same paragraph. It is unclear how the various risk factors were grouped. It would be helpful to add subheadings to clarify this.

Response: Thanks for this suggestion, and the subheadings have already added in the revised manuscript.

Question 24: Results: “systemic disease” as a risk factor is not helpful or clinically relevant. This needs to be specified as to which specific systemic disease was considered or otherwise removed from the analysis.

Response: Thanks for this suggestion. The systemic disease was defined based on individual study, and the stratified data based on systemic disease was not available. We have already addressed this comment in Limitation section.

Question 25: Discussion: “we noted that other races versus white race were associated with an increased risk of DES, which is significantly related to the climate type.” Is race a risk factor independent of climate type? Elaborate on how climate type mediated this effect.

Response: Thanks for this suggestion. The climate type was not addressed in nearly all of included studies, and this comment have already addressed in Limitation section.

Question 26: Discussion: “anti-hypertensive medication could increase the risk of DES”. What is the mechanism of this association?

Response: Thanks for this suggestion, and this sentence have already changed into: “A potential reason for this could be hypertension was not direct affect the risk of DES, while the use of anti-hypertensive medication could increase the risk of DES.[32] In addition, the risk of DES were not increased in hypertensive patients treated with anti-hypertensive medications, such as Angiotension Converting Enzyme inhibitors might play a protective role on the risk of DES.[33]”

Question 27: Discussion: “The role of rosacea could be explained by its significant relation to corneal neovascularization and perforation, which could induce vision loss and ocular comorbidities.[85]” This relation is poorly described. Rosacea is a well known risk factor for DES due to is pro-inflammatory effects that induce meibomian gland dysfunction and evaporative DES.

Response: Thanks for this suggestion, and this sentence have already changed into: “Rosacea is a well known risk factor for DES due to is pro-inflammatory effects that induce meibomian gland dysfunction and evaporative DES.[85]”

Question 28: Discussion: “Studies have already found that thyroid disease is significantly related to ocular surface damage, elevated lip aperture” - ‘elevated lip aperture’ should read ‘eyelid retraction’

Response: Thanks for this suggestion, and ‘elevated lip aperture’ have already changed into ‘eyelid retraction’ in the revised manuscript.

Question 29: Discussion: a major limitation is that the impact of confounding variables is unaddressed by certain studies, and multivariable associations were only reported for certain risk factors. Given the large proportion of cross-sectional studies, recall bias is likely a significant issue in these results.

Response: Thanks for this suggestion. The adjusted factors have already mentioned in Table 1. Moreover, the following sentence have already added in Limitation section: “First, this study contained cross-sectional, retrospective, and prospective observational studies, and the results could affect by recall bias, which restricting the assessment of causality relationships between risk factors and DES.”

Question 30: Figure 2: p-value column - unsure why the p-values displayed in this way, as if multiple numbers are written on top of one another? What is the significance of the blue/gray background behind the forest plot for each endpoint?

Response: Thanks for this suggestion, and the Figure 2 have already changed in the revised manuscript. Moreover, the blue/gray background behind in the forest have already revised in Supplementary file.

Reviewer #2:

General comments: This is a very well written meta-analysis regarding the potential risk factors for dry eye syndrome. Nevertheless, risk factors for DES are widely known, therefore, my question to the authors is:

In which way this meta analysis contributes to the literature already published regarding the risk factors for DES.

Response: We appreciate the reviewer given this kindly comments. Systematic reviews and meta-analyses are the most powerful tools in evaluating inconsistencies in risk factors. Our study designed as meta-analysis, and the inconsistent results for the risk factors of DES could determined. Moreover, the pooled effect estimates for the risk factors of DES could obtained based on large number of studies, and the results were stability.

Attachment

Submitted filename: Response to reviewer.docx

Click here for additional data file. (22.6KB, docx)

Decision Letter 1

Michael Mimouni

4 Apr 2022

PONE-D-21-35192R1Identified risk factors for dry eye syndrome: A systematic review and meta-analysisPLOS ONE

Dear Dr. Wei,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 19 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Mimouni

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The reviewer thanks the authors for their attempt at revising the manuscript. While improved, the manuscript still has a few limitations as noted below:

1. Conclusion, Abstract: “This study reported the comprehensive risk factors for dry eye syndrome, including demographic information, clinical characteristics, and comorbidities.” This sentence is not suitable as the last sentence of the abstract. Instead, the authors should discuss the implications of their research (i.e. why identification of these risk factors is important to improve clinical care) or alternatively discuss other areas of research that could be explored.

2. The manuscript should be thoroughly proofread by a native English speaker. For instance, this sentence contains multiple grammatical errors: “Moreover, the occupational risk factor of visual display terminal (VDT) use was related to the progression of DES, which could explained by decreases blink rate and increases the proportion of incomplete blinks could causing the increased exposure of the ocular surface to the environment”. A more appropriate sentence would be: “Moreover, the occupational risk factor of visual display terminal (VDT) use was related to the progression of DES, which could be explained by a decreased blink rate and increased proportion of incomplete blinks that could be caused by the increased exposure of the ocular surface to the environment”. In some sections, the language is so poor that it is uninterpretable: “which restricting the assessment of causality relationships between risk factors and DES”.

3. The search strategy is still insufficient to permit replication of the search by an independent researcher. The authors should specify the search strategy in a line-by-line format in a table that outlines clearly what term was searched, how terms were combined, and whether any restrictions were applied. The search should be updated to March 2022. In the table, the authors should highlight whether each term was a MeSH subject heading or a text based term.

4. The authors note that studies which assessed risk factors in at least 3 cohorts were included. The authors should cite the meta-analysis in Lancet Global Health that they followed for this methodology. I would advise changing ‘cohorts’ to ‘studies’ to make this sentence clearer in the Methods.

5. The authors note that “this study contained cross-sectional, retrospective, and prospective observational studies, and the GRADE evaluation was not applied for certainty of findings.” This reviewer believes it is important to conduct a GRADE evaluation for this meta-analysis especially because the evidence comes primarily from observational studies which are by their nature susceptible to bias. To provide readers with an indication of the certainty of evidence, the GRADE evaluation should be integrated.

6. The authors have discussed the variable definitions of DED in the limitations section, however in the baseline characteristics section of the results the authors should specify how different studies defined DED. This is important for readers to understand.

7. The sentence “we noted that other races versus white race were associated with an increased risk of DES, which is significantly related to the climate type” should be deleted because there is not evidence to support the notion that DES in different races is attributable to climate type as opposed to other factors.

Reviewer #2: Thank you for addressing my question and improving the shortcoming section. I do not have any more questions or comments to the authors.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 19;17(8):e0271267. doi: 10.1371/journal.pone.0271267.r004

Author response to Decision Letter 1

19 May 2022

Reviewer #1:

General comments: The reviewer thanks the authors for their attempt at revising the manuscript. While improved, the manuscript still has a few limitations as noted below:

Response: As behalf of all co-authors, I would like to appreciate this referee due to thoughtful comments proposed by the peer review. After we revised the manuscript, those significant issues could be changed.

Question 1: Conclusion, Abstract: “This study reported the comprehensive risk factors for dry eye syndrome, including demographic information, clinical characteristics, and comorbidities.” This sentence is not suitable as the last sentence of the abstract. Instead, the authors should discuss the implications of their research (i.e. why identification of these risk factors is important to improve clinical care) or alternatively discuss other areas of research that could be explored.

Response: Thanks for this suggestion, and the conclusion have already changed into: “This study reported risk factors for dry eye syndrome, and identified patients at high risk for dry eye syndrome.”

Question 2: The manuscript should be thoroughly proofread by a native English speaker. For instance, this sentence contains multiple grammatical errors: “Moreover, the occupational risk factor of visual display terminal (VDT) use was related to the progression of DES, which could explained by decreases blink rate and increases the proportion of incomplete blinks could causing the increased exposure of the ocular surface to the environment”. A more appropriate sentence would be: “Moreover, the occupational risk factor of visual display terminal (VDT) use was related to the progression of DES, which could be explained by a decreased blink rate and increased proportion of incomplete blinks that could be caused by the increased exposure of the ocular surface to the environment”. In some sections, the language is so poor that it is uninterpretable: “which restricting the assessment of causality relationships between risk factors and DES”.

Response: Thanks for this suggestion, and the English revision have already performed by Editage Company.

Question 3: The search strategy is still insufficient to permit replication of the search by an independent researcher. The authors should specify the search strategy in a line-by-line format in a table that outlines clearly what term was searched, how terms were combined, and whether any restrictions were applied. The search should be updated to March 2022. In the table, the authors should highlight whether each term was a MeSH subject heading or a text based term.

Response: Thanks for this suggestion, and the details search strategy in PubMed have already added in S1 file.

Question 4: The authors note that studies which assessed risk factors in at least 3 cohorts were included. The authors should cite the meta-analysis in Lancet Global Health that they followed for this methodology. I would advise changing ‘cohorts’ to ‘studies’ to make this sentence clearer in the Methods.

Response: Thanks for this suggestion, and this articles have already cited in the revised manuscript. Moreover, the ‘cohorts’ have already changed into ‘studies’.

Question 5: The authors note that “this study contained cross-sectional, retrospective, and prospective observational studies, and the GRADE evaluation was not applied for certainty of findings.” This reviewer believes it is important to conduct a GRADE evaluation for this meta-analysis especially because the evidence comes primarily from observational studies which are by their nature susceptible to bias. To provide readers with an indication of the certainty of evidence, the GRADE evaluation should be integrated.

Response: We acknowledge the importance of GRADE, while 39 of included studies designed as cross-sectional studies, and the causality relationships between risk factors and DES were not available. Moreover, the quality of included studies were assessed using the Newcastle-Ottawa Scale, and the results are listed in S1 table.

Question 6: The authors have discussed the variable definitions of DED in the limitations section, however in the baseline characteristics section of the results the authors should specify how different studies defined DED. This is important for readers to understand.

Response: Thanks for this suggestion, and the following sentence have already added in Results section: “The DES definition based on questionnaire were reported in 33 studies, 10 studies used TBUT, ST, or FSS defined DES, 3 studies applied ICD9 code and the remaining 2 studies used clinician-diagnosed defined DES.”

Question 7: The sentence “we noted that other races versus white race were associated with an increased risk of DES, which is significantly related to the climate type” should be deleted because there is not evidence to support the notion that DES in different races is attributable to climate type as opposed to other factors.

Response: Thanks for this suggestion, and this sentence have already removed in the revised manuscript.

Reviewer #2:

General comments: Thank you for addressing my question and improving the shortcoming section. I do not have any more questions or comments to the authors. 

Response: We appreciate the reviewer given this kindly comments.

Attachment

Submitted filename: Response to reviewer.docx

Click here for additional data file. (13.8KB, docx)

Decision Letter 2

Michael Mimouni

28 Jun 2022

Identified risk factors for dry eye syndrome: A systematic review and meta-analysis

PONE-D-21-35192R2

Dear Dr. Wei,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michael Mimouni

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The reviewer thanks the author for revising the manuscript based on earlier feedback. I have no further comments.

Reviewer #2: I do not have more comments for the authors. Thank you for answering all the reviewers questions and improving the script.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Michael Mimouni

10 Aug 2022

PONE-D-21-35192R2

Identified risk factors for dry eye syndrome: A systematic review and meta-analysis

Dear Dr. Wei:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Mimouni

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA 2020 checklist.

    (PDF)

    Click here for additional data file. (118.1KB, pdf)
    S1 Table. Quality scores of prospective cohort studies using Newcastle-Ottawa Scale.

    (DOCX)

    Click here for additional data file. (20.7KB, docx)
    S1 File. Search strategy in PubMed.

    (DOCX)

    Click here for additional data file. (11KB, docx)
    S2 File. Forest plots for the risk factors of dry eye syndrome.

    (DOCX)

    Click here for additional data file. (3.1MB, docx)
    S3 File. Sensitivity analyses for the risk factors of dry eye syndrome.

    (DOCX)

    Click here for additional data file. (86.5MB, docx)
    S4 File. Funnel plots for the risk factors of dry eye syndrome.

    (DOCX)

    Click here for additional data file. (94.5MB, docx)
    Attachment

    Submitted filename: Response to reviewer.docx

    Click here for additional data file. (22.6KB, docx)
    Attachment

    Submitted filename: Response to reviewer.docx

    Click here for additional data file. (13.8KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES